Xceed 'Hones in' on Breast, Colon Cancer; Plans to Launch First FDA-Cleared Assay in '10
April 28, 2009
Xceed 'Hones in' on Breast, Colon Cancer; Plans to Launch First FDA-Cleared Assay in '10
CEO David Deems said that Xceed has decided to engage the FDA early in the development process because the agency's "thinking on these types of tests is evolving" and the company would like to "stay connected to whatever approach they are thinking of putting in place."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GMU Phosphoproteomic Studies Offer Potential Clinical Insights on Breast, Colorectal Cancers
October 12, 2012 / ProteoMonitor - Agendia Lands $1.8M for EU Cancer Projects
July 21, 2011 / GenomeWeb Daily News - Researchers ID Gastric Cancer Biomarker Aimed for Use in DTC Tests in US, China
May 6, 2011 / ProteoMonitor - BSI Merges with MBC to Secure Access to Nanoarray Technology and New Academic and Pharma Markets
September 17, 2010 / ProteoMonitor - Genomic Health's Colon Cancer Dx Meets Prognostic, Not Predictive, Endpoint; Will Debut in 2010
April 15, 2009 / Pharmacogenomics Reporter